WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
"The preclinical data for REM-422 provide strong therapeutic rationale for our ongoing Phase I study in AML and High-Risk MDS," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix ...
Dr. Koneru has extensive experience and expertise in the field of drug development with a track record of advancing novel therapeutics from early development through later-stage clinical programs. She ...
WATERTOWN, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
The c-MYB oncogene plays a key role in hematopoietic cell differentiation and proliferation. Genetic abnormalities and dysregulation of MYB have been found in several cancers, including adenoid cystic ...
The MarketWatch News Department was not involved in the creation of this content. WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company ...
Study Evaluates Antitumor Activity and Safety of REM-422, a First/Best-in-Class Small Molecule MYB mRNA Degrader, in Patients with Adenoid Cystic Carcinoma WATERTOWN, Mass., Oct. 13, 2025 (GLOBE ...
WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback